Currier Plastics Acquires Sage Product Development to Expand Medical Device Capabilities

Currier Plastics has completed the acquisition of Sage Product Development, a medical device engineering, design, and development company based in Foxborough, Massachusetts, as it expands its contract development and manufacturing capabilities for healthcare and life sciences customers.

The transaction was announced on August 7, 2026, by Sheridan Capital Partners, the healthcare-focused private equity firm that invested in Currier in September 2025. Financial terms of the Sage acquisition were not disclosed in the announcements reviewed.

The deal brings together Currier’s capabilities in precision plastics manufacturing with Sage’s experience in early-stage medical device development. The combined business is intended to support customers through a broader portion of the product lifecycle, from initial concepts and feasibility assessments to design, validation, manufacturing and commercial production.

Sage Adds Product Development Expertise

Founded in 2011, Sage Product Development works with medical device companies ranging from startups to multinational manufacturers. Its services include early concept and feasibility work, mechanical and biomedical engineering, industrial design, project management, quality and regulatory support, and low- to mid-volume contract manufacturing.

The company has experience across disposable and reusable medical devices, implants, electromechanical systems, flexible endoscopes, catheter-based systems, and other minimally invasive technologies. According to the acquisition announcement, Sage has worked with more than 100 customers and contributed to technologies associated with more than 220 issued patents.

Sage is also registered to ISO 13485:2016, the quality management system standard widely used by medical device manufacturers and suppliers. Its existing manufacturing activities are particularly focused on early production requirements such as verification and validation builds, clinical studies and initial market launches.

For Currier, the acquisition expands capabilities upstream from large-scale production. Chief Executive Andrew McLean said the combination would allow customers to work with a single partner from the concept stage through commercial-scale manufacturing.

Currier Builds a Broader Medical Manufacturing Platform

Founded in 1982 and headquartered in Auburn, New York, Currier manufactures precision plastic components, with a significant focus on healthcare and life sciences applications. Its capabilities include injection molding, blow molding, design engineering, material selection, assembly, and production in controlled cleanroom environments.

Sheridan Capital Partners invested in Currier in September 2025 as part of a strategy focused on medical contract manufacturing. Sheridan said at the time that it intended to support both organic expansion and strategic acquisitions.

That acquisition strategy has subsequently broadened Currier’s manufacturing platform. In addition to Sage, Currier has acquired medical contract manufacturers Springboard Manufacturing and MOS Plastics, extending its position in precision plastics and outsourced medical manufacturing.

Adding Sage represents a different type of expansion because it increases Currier’s involvement in the engineering and development stages that take place before manufacturing volumes increase.

Sustainability Decisions Can Begin at the Design Stage

Although the acquisition announcement is primarily focused on medical device development and manufacturing capabilities rather than environmental targets, the combination has potential sustainability implications.

For plastic-intensive products, many decisions affecting material consumption and eventual waste generation are made during product design. Material selection, component geometry, manufacturing methods, product durability, packaging, and whether a device is designed for single or repeated use can influence its resource footprint throughout its lifecycle.

Bringing design engineering and commercial manufacturing within a more integrated development process could therefore give manufacturers additional opportunities to evaluate manufacturability and material efficiency before designs are locked into large-scale production.

Sage states that its engineers consider manufacturability during product development, including for both reusable and single-use medical devices. Currier, meanwhile, maintains an environmental programme covering alternative resins, recycling, packaging, manufacturing efficiency and energy consumption.

Currier says it has investigated bio-based additives and alternative resin options, including the use of reprocessed materials where product requirements permit. Its sustainability programme also includes returnable packaging systems, recycling instead of landfill disposal and energy-efficiency measures within its facilities.

The company reports annual facility energy savings of 42% under its energy-efficiency programme and says it has moved toward electric and servo-driven production machinery. These are company-reported figures rather than independently verified emissions reductions.

Medical applications nevertheless impose significant constraints on the use of recycled or alternative materials because components must satisfy safety, performance, cleanliness and regulatory requirements. Sustainability improvements in this sector therefore depend not only on substituting materials but also on reducing production scrap, improving process efficiency, optimising component design and evaluating where reusable systems can safely replace disposable products.

Growing Importance of Integrated Suppliers

The Currier-Sage transaction also reflects continued consolidation among specialist suppliers serving the medical technology industry.

Medical device manufacturers increasingly rely on contract development and manufacturing organisations for engineering, regulatory support, cleanroom production, assembly and supply-chain management. Combining those functions can reduce the number of handovers between development and production teams and may shorten the path between prototype development and commercial manufacturing.

For sustainability teams, earlier coordination between designers, material specialists and manufacturing engineers can also be important. Changes to resin types, component mass or manufacturing processes are generally easier to evaluate during development than after a medical product has completed validation and entered regulated commercial production.

The acquisition does not itself establish new environmental commitments for either Currier or Sage. Its significance for the net-zero transition lies instead in the creation of a more vertically integrated medical manufacturing platform in which engineering, materials and manufacturing decisions can potentially be considered together.

As healthcare companies face growing pressure to reduce waste and emissions while maintaining stringent patient-safety requirements, the ability to address environmental performance during product development could become an increasingly important capability for medical manufacturing partners.

Source: www.plasticsnews.com